Gene Therapy Market Seeing 7.5%CAGR Surge to 2023 Dominated by application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious disease, Other Diseases


The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.

Request for a sample copy of this report @

The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Request for a Discount of this report @

KEY PLAYERS PROFILED: Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, NewLink Genetics Corp.


This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.

The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.

In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.

The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

By Vector Type

Viral vector




Adeno Associated Virus

Herpes Simplex Virus


Vaccinia Virus


Non-viral vector

Naked/Plasmid Vectors

Gene Gun




By Gene Type



Tumor Suppressor



Growth factors



By Application

Oncological Disorders

Rare Diseases

Cardiovascular Diseases

Neurological Disorders

Infectious disease

Other Diseases

Table of content:


1.1. Report description

1.2. Key benefits

1.3. Key market segments

1.4. Research methodology

1.4.1. Secondary research

1.4.2. Primary research

1.4.3. Analyst tools and models


2.1. CXO perspective


3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top winning strategies Top winning strategies, by year, 2015-2017* Top winning strategies, by development, 2015-2017* (%) Top winning strategies, by company, 2015-2017*

3.3. Top player positioning, 2016

3.4. Porters five forces analysis

3.5. Market dynamics

3.5.1. Drivers High investment for R&D activities pertaining to gene therapy Increase in prevalence of cancer Growth in awareness regarding gene therapy

3.5.2. Restraints High cost associated with gene therapies Unwanted immune responses

3.5.3. Opportunity Untapped potential for emerging markets


4.1. Overview

4.1.1. Market size and forecast

4.2. Viral vectors

4.2.1. Key market trends

4.2.2. Key growth factors and opportunities

4.2.3. Market size and forecast

4.2.4. Market Analysis by country

4.2.5. Adenovirus

4.2.6. Lentivirus

4.2.7. Retrovirus

4.2.8. Adeno-associated virus

4.2.9. Herpes simplex virus

4.2.10. Poxvirus

4.2.11. Vaccinia virus

4.2.12. Others

4.3. Nonviral techniques

4.3.1. Key market trends

4.3.2. Key growth factors and opportunities

4.3.3. Market size and forecast

4.3.4. Market Analysis by country

4.3.5. Naked plasmid vector

4.3.6. Gene gun

4.3.7. Electroporation

4.3.8. Lipofection

4.3.9. Others

For More:

About Us:

Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers at one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact us:
Mr. Abhishek Paliwal

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States


Toll Free:+1-800-910-6452